Trial Profile
Phase I Dose Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 06 May 2014 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
- 24 Mar 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011, as per ClinicalTrials.gov record.
- 24 Mar 2011 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.